Lenz, Heinz-Josef

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., Boland, P. M., Crysler, O., Wu, C., Grothey, A., et al. (2019) · Annals of Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study

Andre, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., De La Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 63

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Lenz, H.-J., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Elez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 61

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

Kopetz, S., McDonough, S. L., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Raghav, K. P. S., Morris, V. K., Wang, S. E., et al. (2017) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 58

Association of Coffee Intake with Survival in Patients With Advanced or Metastatic Colorectal Cancer

Mackintosh, C., Yuan, C., Ou, F.-S., Zhang, S., Niedzwiecki, D., Chang, I.-W., O’Neil, B. H., Mullen, B. C., Lenz, H.-J., Blanke, C. D., et al. (2020) · JAMA Oncology

Coffee research and impactsColorectal Cancer Treatments and Studies

Cited by 52

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer

Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers

Pancreatic and Hepatic Oncology ResearchWnt/β-catenin signaling in development and cancer

Cited by 51

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 49

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Winder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 46

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 42

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial

Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischl, J., Vonk, R., Lenz, H.-J., Tabernero, J., Siena, S., Grothey, A., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 26

TAS‐102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial

Mayer, R. J., Ohtsu, A., Yoshino, T., Falcone, A., Garcia-Carbonero, R., Tabernero, J., Sobrero, A. F., Peeters, M., Benedetti, F., Makris, L., et al. (2016) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 21

Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial

Schirripa, M., Zhang, W., Heinemann, V., Cao, S., Okazaki, S., Yang, D., Loupakis, F., Berger, M. D., Ning, Y., Miyamoto, Y., et al. (2017) · International Journal of Cancer

Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors

Cited by 11

First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

Andre, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G., Schenker, M., et al. (2025) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 9

Differential Response and Resistance to KRAS-Targeted Therapy

Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 7

436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

Ahn, D. H., Erlander, M., Ridinger, M., Samuëlsz, E., Barzi, A., Bekaii-Saab, T., & Lenz, H. J. (2020) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 5

Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer

Arai, H., Millstein, J., Loupakis, F., Stintzing, S., Wang, J., Battaglin, F., Kawanishi, N., Jayachandran, P., Soni, S., Zhang, W., et al. (2021) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 2